Cargando…
Update on the utility of prognostic biomarkers in ovarian cancer
There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the se...
Autor principal: | Markman, Maurie |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924732/ https://www.ncbi.nlm.nih.gov/pubmed/20948749 http://dx.doi.org/10.3410/M1-31 |
Ejemplares similares
-
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009) -
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018) -
New developments in the anti-neoplastic drug management of ovarian cancer
por: Markman, Maurie
Publicado: (2013) -
Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer
por: Markman, Maurie
Publicado: (2010) -
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
por: Markman, Maurie
Publicado: (2011)